> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Proposed Streamlined Approval Process for Individualized Gene-Editing Therapies
- URL: https://www.fdaweb.com/proposed-streamlined-approval-process-for-individualized-gene-editing-therapies/
- Published: 2026-10-27T19:05:18.000Z
- Updated: 2026-10-27T19:05:18.000Z
- Author: David McFarland
- Tags: Biologics

FDA has posted a draft guidance outlining a regulatory framework that would allow manufacturers of individualized genome-editing (GE) therapies to include multiple patient-specific treatment variants in a single BLA and add additional variants after approval without necessarily conducting new clinical trials.

The [draft guidance](https://www.fda.gov/media/195887/download?ref=fdaweb.com), *Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management*, is intended to facilitate development of treatments for rare genetic diseases in which individual patients may have different disease-causing mutations within the same gene.

“Because a single product variant typically targets only one gene variant, a GE product intended to address a range of gene variants may include a set of modified GE components,” the agency says. “The physical characteristics of these GE components that differ among product variants are termed variable features. A BLA for an individualized GE product may therefore contain many product variants, each sharing the same core design and differing only in the GE components used to address each patient's specific gene variant.

“Defining the allowable limits of feature variation in the BLA,” it continues, “serves two purposes: establishing the boundaries of the product and facilitating the post-licensure addition of new product variants that fall within those boundaries. Importantly, is framework provides a way for applicants to add new product variants to a BLA based on in vitro data without additional clinical studies.”

Under the proposed approach, sponsors could establish an "individualized feature space" (IFS) defining the permissible variations in genome-editing components, such as guide RNA sequences, while maintaining the same underlying editing mechanism and intended therapeutic outcome.

FDA says new product variants falling within an approved IFS could generally be added through BLA supplements supported by laboratory data demonstrating adequate activity and safety, without requiring clinical studies for each additional variant.

The approach would allow sponsors to leverage clinical evidence generated from previously studied variants, provided the relationship between laboratory findings and clinical safety and effectiveness is sufficiently understood and predictable.

Sponsors would be expected to establish criteria for on-target editing activity and assess potential unintended or off-target genetic changes for each variant, the agency says. The initial BLA would also need to justify how the clinical evidence supports the full range of variations covered by the proposed IFS.

FDA recommends that manufacturers establish post-approval change management protocols specifying the testing and documentation required when adding new variants. Manufacturing processes would need to accommodate the anticipated variations while maintaining appropriate product quality controls.

Changes that expand the established IFS would require prior-approval supplements, with additional clinical evidence potentially necessary depending on the risks, it adds. Changes fundamentally altering the editing mechanism or introducing significant new risks would require a separate BLA.